KKCG sold a 4.27% stake in Allwyn to J&T Arch Investments Sicav, an investor fund listed on the Prague Stock Exchange. In connection with the deal, Schellenberg Wittmer – alongside A&O Shearman – advised
Tags :Oliver Triebold
Abacus Medicine Group – a Danish group active across the modern healthcare sector – completed the acquisition of Swiss Cardio Technologies. In connection the deal Shellenberg Wittmer advised the buyer, while Baker McKenzie Switzerland represented the shareholders
Schellenberg Wittmer advised German retailer Obi on the takeover its Swiss store line-up from former franchise partner Migros. Following the transaction, Obi Group takes over the entire Swiss store fleet, previously contracted-out to franchise partner
Schellenberg Wittmer advised Bioventure Club Deal Nine & Co KG in a Series C financing round of the Swiss Aphaia companies, which are clinical-stage pharmaceutical companies that have developed proprietary treatment methods targeting obesity and
Schellenberg Wittmer recently advised Gilde Healthcare’s Private Equity Fund on the acquisition of a majority shareholding in Swiss Dental Solutions (SDS) through UNAC Holding. The transaction, part of an international operational growth and development
Schellenberg Wittmer has advised Arole Holding, the acquisition structure controlled by Swiss entrepreneur and investor Dan Mamane, on the divestiture of Conforama Switzerland to XXXLutz. The transaction was approved by the Swiss competition authority. XXXLutz
The first edition of “Mergers & Acquisitions” co-edited by Florian S. Jörg (partner at Bratschi, pictured left), Urs Gnos (partner at Walder Wyss, pictured center) and Schellenberg Wittmer corporate/m&a partner Lorenzo
Schellenberg Wittmer has advised Bioventure Club Deal Nine & Co KG on a Series B Financing Round of the Swiss Aphaia Companies, which are clinical stage pharma companies that have developed proprietary treatment methods targeting
Perfect Holding announced the completion of the reverse takeover transaction (RTO) with Kinarus, a clinical-stage biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of viral, respiratory, and ophthalmic disease.
Kinarus, a privately owned clinical-stage biopharmaceutical company active in the development of novel treatments for patients suffering from serious viral, respiratory and ophthalmic diseases, signed a Transaction Agreement with SIX-listed Perfect Holding regarding Perfect Holding’
